Login Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

  • Watchlist

    Keep track of companies that you follow and research.

  • 10 Years of Data

    Full access to our data with predictions and indicators that we calculate daily.

  • Screener

    Full access to our screener with tons of custom values and customizable email notifications.

  • XLS Exports

    Excel export of financials and screeners you define and save.

Subscribe now
Screener Weekly Summary

Axsome Therapeutics, Inc. AXSM

Healthcare  —  Biotechnology
Overview Business Profile Analyst Commentary Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K
Quarterly (Descending) Quarterly (Ascending) Annual (Descending) Annual (Ascending) TTM (Descending) TTM (Ascending)

Financial statements are limited to most recent four years or quarters for non-powerpack users

Ten years worth of data (where available), most important trends and XLS exports are available for our Powerpack users.

Register an account and get your Powerpack now or Login
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
P/E ratio 0.00 0.00 0.00 0.00 — — — — — —
P/S ratio 14.23 10.51 12.94 0.00 — — — — — —
P/FCF ratio 0.00 0.00 0.00 0.00 — — — — — —
P/Operating CF (487.10) (154.72) (115.29) (108.15) — — — — — —
P/B ratio 102.90 71.10 18.33 27.21 — — — — — —
Price to Tangible BV 254.26 0.00 27.86 75.30 — — — — — —
EV/Sales 13.92 10.17 12.17 0.00 — — — — — —
EV/EBITDA 0.00 0.00 0.00 0.00 — — — — — —
EV/Operating CF (95.13) (30.55) (22.70) (24.67) — — — — — —
EV/FCF (94.64) (30.48) (22.61) (24.53) — — — — — —
Quick Ratio 1.44 1.99 3.46 2.47 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Current Ratio 1.55 2.11 3.63 2.54 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Net Debt/EBITDA 1.29 0.49 0.94 0.61 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Debt/Assets 17.68% 32.30% 30.27% 28.56% ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Debt/Equity 1.38 3.22 0.93 0.86 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Asset Turnover 1.01 0.67 0.59 0.24 ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡
Operating CF/Net income 0.51 0.45 0.61 0.62 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Capex/Depreciation (0.05) (0.03) (0.06) (0.12) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Depreciation/Fixed assets 18.45 18.15 11.12 8.15 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Interest Coverage 0.00 0.00 0.00 0.00 ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡
ROE (252.11%) (231.63%) (159.21%) (298.97%) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
ROA (29.11%) (49.66%) (52.02%) (89.27%) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
ROIC 0.00% 0.00% 0.00% (3,307.37%) ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡
Cash ROIC (17.62%) (23.20%) (19.32%) (28.94%) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Return on Tangible Assets (86.93%) (112.39%) (65.32%) (124.92%) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Accounts Receivable Turnover 3.48 3.26 4.08 0.00 — — — — — —
Accounts Payable Turnover 0.69 0.59 0.66 0.20 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Inventory Turnover 2.17 2.16 2.68 0.00 ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡
Average Days of Receivables 128.32 134.38 127.90 275.00 — — — — — —
Average Days of Payables 503.83 789.09 569.65 2,710.82 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Days of Inventory on Hand 214.78 172.42 211.94 303.35 ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡
Research and Development Expense of Revenue 28.70% 48.50% 36.20% 115.81% ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡
Selling, General and Administrative Expense of Revenue 89.37% 106.65% 119.41% 318.27% ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡
Intangible Assets out of Total Assets 0.08 0.10 0.11 0.21 ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡
Share Based Compensation of Revenue 14.68% 22.09% 23.14% 75.40% ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡
Graham Net Nets 0.00 (0.01) 0.03 0.01 — — — — — —
Graham Number 0.00 0.00 0.00 0.00 — — — — — —
Earnings Yield (2.02%) (7.08%) (6.75%) (6.23%) — — — — — —
Free Cash Flow Yield (1.03%) (3.17%) (4.16%) (3.93%) — — — — — —
Revenue per Share 12.83 8.05 5.96 1.23 ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡
Operating CF per Share (1.88) (2.68) (3.19) (2.87) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Capex per Share (0.01) (0.01) (0.01) (0.02) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Free Cash Flow per Share (1.89) (2.69) (3.21) (2.88) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Cash per Share 6.49 6.58 8.50 4.94 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Shareholders Equity per Share 1.77 1.19 4.20 2.69 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Interest Debt per Share 0.00 0.00 0.00 0.00 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Book value per Share 1.77 1.19 4.20 2.69 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Free Cash Flow (93.88) (128.68) (145.66) (117.21) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Working Capital 210.15 254.96 365.41 149.08 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Capital Expenditures (0.48) (0.27) (0.58) (0.70) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Net Current Asset Value (12.52) (26.42) 107.00 23.72 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Average Receivables 183.23 118.41 66.26 — — — — — — —
Average Payables 68.77 56.34 39.64 25.88 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Average Inventory 21.84 15.43 9.73 — — — — — — —
Average Assets 629.15 578.37 459.86 209.63 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Average Common Equity 72.65 124.00 150.27 62.59 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
EV/EBIT 0.00 0.00 0.00 0.00 — — — — — —
Capex to Sales 0.00 0.00 0.00 0.01 ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡
Net Profit Margin (28.69%) (74.47%) (88.41%) (373.99%) ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡
Price to Operating Income 0.00 0.00 0.00 0.00 — — — — — —